Publications

5539 Results

Determinants of prostate specific antigen (PSA) normalization in prostate cancer (PCa) patients (pts) treated with androgen deprivation (AD) on Southwest Oncology Group (SWOG) study 9346 (INT-0162).

Authors
CM Tangen;M Hussain;G Wilding;EJ Small;L Goldenberg;A Akdas;ED Crawford
Journal / Conference
Proc of the American Society of Clinical Oncology 22:396(#1591)
Year
2003
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-9346

African Americans have worse survival in hormone-related cancers. a Southwest Oncology Group (SWOG) study.

Authors
JM Unger;CA Coltman, Jr;FR Appelbaum;B Barlogie;ED Crawford;RI Fisher;DR Gandara;RB Livingston;M Markman;KS Albain
Journal / Conference
Proc of the American Society of Clinical Oncology 22:529(#2127)
Year
2003

Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09).

Authors
KS Albain;CB Scott;VR Rusch;AT Turrisi;FA Shepherd;C Smith;DR Gandara;DH Johnson;MR Green;RC Miller
Journal / Conference
Proc of the American Society of Clinical Oncology 22:621(#2497)
Year
2003
Research Committee(s)
Lung
Study Number(s)
SWOG-9336

A phase II study of flavopiridol (Flavo) in patients (pts) with advanced renal cell cancer: results of Southwest Oncology Group trial S0109.

Authors
PJ Van Veldhuizen;JR Faulkner;PN Lara;RC Flanigan;PH Gumerlock;ED Crawford
Journal / Conference
Proc of the American Society of Clinical Oncology 22:387(#1553)
Year
2003
Research Committee(s)
Genitourinary
Study Number(s)
S0109

S0003: Paclitaxel/carboplatin (PC) v PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III Southwest Oncology Group (SWOG) trial.

Authors
SK Williamson;JJ Crowley;PN Lara;RW Tucker;J McCoy;DHM Lau;DR Gandara
Journal / Conference
Proc of the American Society of Clinical Oncology 22:622(#2502)
Year
2003
Research Committee(s)
Lung
Study Number(s)
S0003

Intergroup 0144 - phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV.

Authors
SR Smalley;J Benedetti;S Williamson;J Robertson;B Fisher;J Martenson;AB Benson;M Robert;C Cripps;J Macdonald
Journal / Conference
Proc of the American Society of Clinical Oncology 22:251(#1006)
Year
2003
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-9304 (INT-0144)

Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results.

Authors
RS Benjamin;C Rankin;C Fletcher;C Blanke;M Von Mehren;R Maki;V Bramwell;L Baker;E Borden;GD Demetri
Journal / Conference
Proc of the American Society of Clinical Oncology 22:814(#3271)
Year
2003
Research Committee(s)
Sarcoma
Study Number(s)
S0033

Surgical variables impact bladder cancer outcomes: a cooperative group report.

Authors
HW Herr;J Faulkner;HB Grossman;ED Crawford
Journal / Conference
Proc of the American Society of Clinical Oncology 22:383(#1540)
Year
2003
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8710 (INT-0080) (EST-1887) (CALGB-8891)

Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIa non-small cell lung cancer (NSCLC) leads to higher than expected risk of death from intercurrent disease (DID).

Authors
HA Wakelee;P Stephenson;SM Keller;H Wagner;A Herskovic;R Komaki;RS Marks;MC Perry;RB Livingston;DH Johnson
Journal / Conference
Proc of the American Society of Clinical Oncology 22:633(#2545)
Year
2003
Research Committee(s)
Lung
Study Number(s)
SWOG-9252 (INT-0115) (EST-3590) (RTOG 91-05) (NCCTG-91-24-51) (CALGB-9393)

Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study.

Authors
RP Whitehead;S McCoy;J Macdonald;SE Rivkin;M Neubauer;S Dakhil;H-J Lenz;M Tanaka;JL Abbruzzese
Journal / Conference
Proc of the American Society of Clinical Oncology 22:272(#1092)
Year
2003
Research Committee(s)
Gastrointestinal
Study Number(s)
S9923